| Similar Articles |
|---|
 |
Chemistry World
June 10, 2013
Phillip Broadwith |
AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer.   |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
Chemistry World
July 15, 2008
Hepeng Jia |
Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients. |
Chemistry World
August 3, 2015
Phillip Broadwith |
AstraZeneca sells off drugs to streamline portfolio Anglo-Swedish pharmaceutical firm AstraZeneca has agreed to sell the rights to two drugs that the company considers lie outside its strategic focus areas. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
The Motley Fool
June 21, 2007
Brian Orelli |
Dumpster Diving in Pfizer's Trash Investors are probably overreacting to Pfizer's decision, but only time -- and clinical trials -- will tell. |
The Motley Fool
May 22, 2009
Brian Orelli |
Novartis Breathes Easier Novartis' investors can breathe a little easier. The company's new treatment for chronic obstructive pulmonary disease -- a.k.a. "smoker's lung" -- passed its three phase 3 trials without so much as a cough. |
The Motley Fool
May 22, 2008
Brian Lawler |
All Is Not Lost for AstraZeneca's Iressa AstraZeneca's Iressa gets a little pep back. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
Bio-IT World
October 10, 2003
Kevin Davies |
Iressa's Trials and Tribulations The Iressa experience highlights the enormous stakes surrounding breakthrough therapies. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
July 15, 2011
Brian Orelli |
Vical Transplants Some Firepower A licensing deal with Astellas gives the company a shot in the arm. |
Chemistry World
November 9, 2015
Phillip Broadwith |
AstraZeneca to buy ZS Pharma for ion-balance drugs AstraZeneca has agreed to buy US specialist drug company ZS Pharma for around $2.7 billion in an effort to bolster its drug pipeline. |
Chemistry World
September 25, 2013
Phillip Broadwith |
New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets. |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
Chemistry World
March 2, 2015
Phillip Broadwith |
AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea. |
Chemistry World
April 2006
Karen Harries-Rees |
Editorial: Drugs Testing on Trial A drugs trial in the UK that went disastrously wrong last month has raised questions about the ethics of using paid volunteers in clinical trials and the usefulness of animal testing. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion. |
BusinessWeek
March 14, 2005
Arnst & Barrett |
Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
January 5, 2005
Charly Travers |
AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
The Motley Fool
December 1, 2008
Brian Orelli |
It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
Pharmaceutical Executive
December 1, 2008
Ron Feemster |
The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
Chemistry World
December 17, 2015
Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
The Motley Fool
June 30, 2009
Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
BusinessWeek
December 29, 2010
Kelley & Cortez |
AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
Pharmaceutical Executive
September 1, 2013
Stan Bernard |
The Drug Combination Competition Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
The Motley Fool
July 22, 2004
Charly Travers |
Patience With MedImmune While MedImmune has one of the top-selling biologic drugs in the industry, the growth in revenues and earnings is a bit sluggish for what many biotech investors are looking for. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
BusinessWeek
July 17, 2006
Bruce Einhorn |
A Key New Ally In The Cancer War China and its Western trade partners are fighting together on at least one front: the war on cancer. |
